Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study found that the CTLA-4 gene polymorphism (rs733618) has no association with polycystic ovarian syndrome in the studied population.

This report describes a Cronkhite-Canada syndrome patient with severe sepsis and disseminated intravascular coagulation successfully treated using combined therapies, including recombinant human soluble thrombomodulin.

This study found that Complementary and Alternative Medicine practitioners manage PCOS by addressing hormonal imbalances, improving fertility, and enhancing quality of life, incorporating emotional and lifestyle support alongside specific therapies.

In this study, a child's diagnosis of Silver-Russell syndrome was confirmed through phenotype data, genetic testing, and the exclusion of other developmental conditions, revealing a need for a multidisciplinary care approach.

This study found that GAGS scores for acne were higher in younger women with PCOS and a lower BMI, but showed no association with levels of androgen hormones.

This review discusses the diagnostic criteria and treatment options for adolescent polycystic ovary syndrome, highlighting ongoing debates and the need for further research, without presenting new clinical results.

In this study, three cases of Cronkhite-Canada syndrome revealed small bowel mucosal lesions, but these findings did not correlate with clinical symptoms or steroid treatment outcomes.

This study found that a novel saw palmetto supercritical CO2 extract effectively inhibits 5α-reductase type II in vitro, suggesting its potential for promoting prostate health in benign prostatic hyperplasia.

This study assessed the nutritional status of emerging adult women with PCOS and found that while their body measurements were higher than standard, their mean biochemical parameters were within the normal range.

In this study, cyproterone acetate at 2 mg daily was found to be as effective as higher doses in reducing hair growth for hirsute women over 12 months.

This study found that the prevalence of PCOS among Australian women aged 16-29 was 12% using NIH criteria, with fertility concerns being the most distressing aspect for those diagnosed.

This discussion reviews the shift in pharmaceutical strategy towards evidence-based and structure-guided drug development, highlighting ongoing challenges and efforts in computer-aided drug design without presenting new clinical results.

This paper reviews the diagnostic criteria, etiological factors, and treatment approaches for PCOS, highlighting the importance of considering metabolic issues such as insulin resistance and obesity, but reports no new findings.

This review discusses the occurrence of persistent sexual, physical, neurological, and psychiatric side effects known as post-finasteride syndrome after 5x-reductase inhibitor treatment, and emphasizes the importance of evaluating these risks for patients with benign prostatic hyperplasia or androgenic alopecia.

This report details the development of a PSR™ Terminalia extract with antioxidant and anti-aging potential, highlighting its rich composition in phenolic acids, polysaccharides, and organic acids, without new clinical results.

This study observed that women with polycystic ovarian syndrome had higher serum SRAGE levels compared to controls, but the difference was not statistically significant.

This study found that young indigenous South Asian women with polycystic ovary syndrome are more likely to be centrally obese and have metabolic syndrome, particularly with increasing age, higher BMI, and acanthosis nigricans.

This study found that the oral contraceptive containing drospirenone (EE/DRSP) was as effective as EE/CPA in reducing acne lesions, sebum production, and hair growth in women with acne.

This report describes a case of Cronkhite-Canada syndrome diagnosed in a 54-year-old man with symptoms including gastrointestinal polyps, alopecia, skin hyperpigmentation, and severe diarrhea, who experienced significant symptom improvement with azathioprine.

This study in Saudi Arabia found that psychological stress was strongly linked to skin symptoms, with conditions like psoriasis, eczema, acne, rash, and baldness showing significant associations, highlighting the importance of considering stress levels when diagnosing skin issues.

This review proposes renaming polycystic ovarian syndrome to "Hyperandrogenic Persistent Ovulatory Dysfunction Syndrome" to better reflect its diagnostic criteria and promote consistency in research, but reports no new clinical findings.

This review discusses the challenges in diagnosing and managing polycystic ovary syndrome and highlights the need for an integrated, multidisciplinary healthcare model tailored to the diverse needs of women with PCOS; it reports no new clinical findings.

This study found that after 12 weeks of taking the trial product SHPro®, participants reported improvements in prostate symptom scores and erectile function, with confirmed safety.

This study found that serum PSA levels are higher in hirsute women and can be significantly reduced by antiandrogen treatment, suggesting PSA as a marker of androgen action in females.

This study found that women with PCOS who reported the highest levels of physical activity also reported better outcomes in BMI, mental health, and sleep quality, suggesting that enhancing motivation may improve participation in physical activity.

This study found that dermatology consultations in a tertiary care center often led to treatment changes, particularly for complex dermatologic conditions potentially linked to systemic disease.

This review highlights that Cyproterone acetate combined with ethinylestradiol is highly effective for treating severe acne and hirsutism in women with hyperandrogenism, and it also provides benefits for cycle control and mood improvement, according to the analysis of 78 studies.

This study found no evidence that CTLA-4 gene polymorphism (rs733618) plays a role in polycystic ovarian syndrome among the participants.

This phase I study reported that ETC-159, targeting Wnt signalling, showed tolerable safety profiles at doses that inhibit its pathway, though bone turnover markers increased, warranting early and regular monitoring. No tumor responses were observed, but two patients achieved stable disease for several cycles.